Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC)

  • J Med Chem. 2010 Apr 8;53(7):2779-96. doi: 10.1021/jm901488g.
Michael E Jung  1 ,  Samedy Ouk ,  Dongwon Yoo ,  Charles L Sawyers ,  Charlie Chen ,  Chris Tran ,  John Wongvipat
Affiliations
  • 1. Department of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, USA. [email protected]
PMID: 20218717 DOI: 10.1021/jm901488g
Abstract

A structure-activity relationship study was carried out on a series of thiohydantoins and their analogues 14 which led to the discovery of 92 (MDV3100) as the clinical candidate for the treatment of hormone refractory prostate Cancer.

Products